Lipids and Body Mass Index in Antiretroviral‐Experienced People With HIV on Doravirine‐Based Treatments: A Comparison Between Dual or Triple Regimen Versus Bictegravir‐Based Triple Regimen

<b>Objective:</b> To evaluate the lipid profile and body mass index (BMI) in antiretroviral-experienced people living with HIV (PLWH) starting therapy with two doravirine (DOR)-based regimens (dolutegravir (DTG)/DOR or lamivudine (3TC)/tenofovir disoproxil fumarate (TDF)/DOR). <b>Methods:</b> Data from the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective database, including all experienced PLWH who started treatment with DTG/DOR and 3TC/TDF/DOR. To obtain a comparable sample, subjects on emtricitabine (FTC)/tenofovir alafenamide (TAF)/bictegravir (BIC) were matched 1:1 (by sex, age (±1 year), at least one between dyslipidemia and statin use) with those on 3TC/TDF/DOR. <b>Results:</b> Among 355 PLWH on viral suppression, the median age was 53 years; men represented 74.9% of the sample. At baseline, 147 people treated with FTC/TAF/BIC had a better lipid profile and lower CD4 cell count than 147 people treated with 3TC/TDF/DOR; diabetes was less frequent in the latter group. After 6 and 12 months, the BMI did not significantly change in any of the groups. Total cholesterol (TC) level significantly declined in PLWH on 3TC/TDF/DOR but not in FTC/TAF/BIC and remained unchanged in DTG/DOR. LDL-C showed a similar trend, with the most marked decline in the 3TC/TDF/DOR group and no difference in FTC/TAF/BIC. The TC/HDL-C ratio declined significantly in 3TC/TDF/DOR and DTG/DOR but not in FTC/TAF/BIC. Over the entire observation period (median 18 months, interquartile range 10-30), 43 (12.1%) PLWH interrupted the cohort drug, mainly because of adverse events (<i>n</i> = 15), with 12 lost to follow-up and 12 simplifications. <b>Conclusions:</b> The regimens were well tolerated in terms of lipid profile and BMI. Persons treated with 3TC/TDF/DOR triple regimen showed a better lipid profile, as expected, whereas those on DTG/DOR did not show any significant changes.

Authors

Institutions

Publication Details

Journal
AIDS Research and Treatment
Published
2025-01-01
DOI
https://doi.org/10.1155/arat/2040298
Primary Topic
HIV-related health complications and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lipids and Body Mass Index in Antiretroviral‐Experienced People With HIV on Doravirine‐Based Treatments: A Comparison Between Dual or Triple Regimen Versus Bictegravir‐Based Triple Regimen

Antonio Di Biagio, Rita Bellagamba, Katia Falasca, Lucia Taramasso et al.
AIDS Research and Treatment
HIV-related health complications and treatments
article

Lipids and Body Mass Index in Antiretroviral‐Experienced People With HIV on Doravirine‐Based Treatments: A Comparison Between Dual or Triple Regimen Versus Bictegravir‐Based Triple Regimen

Antonio Di Biagio, Rita Bellagamba, Katia Falasca, Lucia Taramasso, Deborah Fiordelisi, Addolorata Masiello, Eleonora Sarchi, Paolo Maggi, Goffredo Angioni, Gabriella Chieffo, Benedetto Maurizio Celesia, Giancarlo Orofino, Giuseppe Vittorio De Socio, Filippo Lagi, Stefano Rusconi, Nicola Squillace, Emanuele Pontali, Elena Ricci, Antonio Cascio, Barbara Menzaghi, Elena Salomoni, Salvatore Martini, Giordano Madeddu, Stefania Piconi, Paolo Bonfanti, Olivia Bargiacchi, Giovanni Francesco Pellicanò, Sergio Ferrara, Maria Aurora Carleo
article en

Abstract

<b>Objective:</b> To evaluate the lipid profile and body mass index (BMI) in antiretroviral-experienced people living with HIV (PLWH) starting therapy with two doravirine (DOR)-based regimens (dolutegravir (DTG)/DOR or lamivudine (3TC)/tenofovir disoproxil fumarate (TDF)/DOR). <b>Methods:</b> Data from the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective database, including all experienced PLWH who started treatment with DTG/DOR and 3TC/TDF/DOR. To obtain a comparable sample, subjects on emtricitabine (FTC)/tenofovir alafenamide (TAF)/bictegravir (BIC) were matched 1:1 (by sex, age (±1 year), at least one between dyslipidemia and statin use) with those on 3TC/TDF/DOR. <b>Results:</b> Among 355 PLWH on viral suppression, the median age was 53 years; men represented 74.9% of the sample. At baseline, 147 people treated with FTC/TAF/BIC had a better lipid profile and lower CD4 cell count than 147 people treated with 3TC/TDF/DOR; diabetes was less frequent in the latter group. After 6 and 12 months, the BMI did not significantly change in any of the groups. Total cholesterol (TC) level significantly declined in PLWH on 3TC/TDF/DOR but not in FTC/TAF/BIC and remained unchanged in DTG/DOR. LDL-C showed a similar trend, with the most marked decline in the 3TC/TDF/DOR group and no difference in FTC/TAF/BIC. The TC/HDL-C ratio declined significantly in 3TC/TDF/DOR and DTG/DOR but not in FTC/TAF/BIC. Over the entire observation period (median 18 months, interquartile range 10-30), 43 (12.1%) PLWH interrupted the cohort drug, mainly because of adverse events (<i>n</i> = 15), with 12 lost to follow-up and 12 simplifications. <b>Conclusions:</b> The regimens were well tolerated in terms of lipid profile and BMI. Persons treated with 3TC/TDF/DOR triple regimen showed a better lipid profile, as expected, whereas those on DTG/DOR did not show any significant changes.

AIDS Research and TreatmentVol. 2025(1)
University of Foggia (IT), Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), University of Sassari (IT), University of Campania "Luigi Vanvitelli" (IT), Università degli Studi di Enna Kore (IT), Ente Ospedaliero Ospedali Galliera (IT), University of Chieti-Pescara (IT), Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT), Ospedale Garibaldi (IT), Azienda Ospedaliera San Gerardo (IT), Alessandro Manzoni Hospital (IT), Ospedale Santa Maria Annunziata (IT), Azienda Ospedaliero-Universitaria Careggi (IT), Azienda Ospedaliero Universitaria Maggiore della Carita (IT), Santissima Trinità (IT), Ospedale di Circolo di Busto Arsizio (IT), Azienda Ospedaliera Universitaria Policlinico "G. Martino" (IT), Azienda Ospedaliera Ospedale Maggiore (IT), Ospedale Policlinico San Martino (IT), Ospedale Sant'Anna (IT), Ospedale D. Cotugno (IT), Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT), Azienda Ospedaliera Ospedale Civile di Legnano (IT), University of Bari Aldo Moro (IT), University of Milano-Bicocca (IT), University of Genoa (IT), University of Palermo (IT)
AstraZeneca, Gilead Sciences, ViiV Healthcare, Mylan, Cilag
Openalex Percentile: Top 61%
HIV-related health complications and treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.